Agatolimod

N/A

Report date: 2025/03/28 20:01:04
NME

Base Information

Drug NameAgatolimod
Drug Alias Name阿托莫德CpG oligodeoxynucleotide 7909ProMuneVaxImmunePF-676 +[11
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide
Mechanisms of ActionImmunostimulantsToll like receptor 9 agonists
TargetsToll like receptor 9
Therapy Area/IndicationsUveal melanomaSkin MelanomaProstatic Neoplasms +[27
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[34
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesPfizer IncColey Pharmaceutical
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsUveal melanomaSkin MelanomaProstatic Neoplasms +[27

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG